All In Biotech

Drug Trial Radar · NCT07525947

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Jade Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.

Conditions

  • Healthy Volunteers (HV)

Interventions

  • JADE101Drug

    JADE101 is supplied as sterile solution to be administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participantsTime frame: Day 1 through 48 weeks
  2. CmaxTime frame: Day 1 through 48 weeks
  3. TmaxTime frame: Day 1 through 48 weeks
  4. AUClastTime frame: Day 1 through 48 weeks
  5. T1/2Time frame: Day 1 through 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel Early Phase Clinical Unit (EPCU)

    Glendale, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.